Integra LifeSciences Holdings Tops Q3 2026 Profit Forecast With $0.59 EPS

Integra LifeSciences (NASDAQ: IART) reported Q3 2026 adjusted EPS of $0.59, beating estimates by $0.02. Revenue rose 2.3% YoY to $411.2M. The Specialty Surgery segment grew 3.9% YoY. FY 2026 guidance: EPS $2.30-$2.40, revenue $1.63B-$1.65B. Analysts are cautiously neutral.

Original reporting
Published Oct 21, 2026, 2:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra LifeSciences Holdings Tops Q3 2026 Profit Forecast With $0.59 EPS — source image
Decision brief

The 30-second read

$IARTNeutralLow
01

Why it matters

The earnings release provides new data but likely has limited trading impact due to modest surprise.

02

Market read

Earnings release adds fresh data for IART but offers limited actionable trade ideas.

03

What to watch

Potential upside if procedure volumes accelerate faster than guidance assumes or pricing holds firm.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Integra LifeSciences reported Q3 2026 results with a slight earnings beat and modest FY guidance.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Q3 2026 earnings beat and FY 2026 guidance released, providing fresh financial data for Integra LifeSciences.

Expected impact

limited upside as the modest beat is likely already priced in

Evidence & confidence

The beat was small (3.5% EPS beat) and the stock showed little movement, indicating market had anticipated the result.

Market effects

Signals modest growth in the medical device sector, with specialty surgery segment outperforming.

Limited impact on broader US market; reflects steady but unspectacular sector performance.

Minimal global relevance beyond investors tracking US medical device equities.

Counterpoint

If investors underestimate the specialty surgery momentum, the stock could rally on incremental volume gains.

Key entities

  • Integra LifeSciences Holdings Corporation

    Medical device manufacturer reporting Q3 earnings.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.